While these effects could be due to therapy-induced expansion of circulating populations of exhausted CD8+ T cells, it is also possible that peripheral tolerance disruption in the tumor-draining lymph node contributes to therapy-induced responses. This evidence concerns the gene CD8A and neoplasm.